Evidence map›Paper›PMID 27017056›Full record

ArticleVirology2016

A novel SIV gag-specific CD4(+)T-cell clone suppresses SIVmac239 replication in CD4(+)T cells revealing the interplay between antiviral effector cells and their infected targets.

Victor I Ayala, Matthew T Trivett, Lori V Coren, Sumiti Jain, Patrick S Bohn, Roger W Wiseman, David H O'Connor, Claes Ohlen, David E Ott

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Virology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Cytotoxic CD4Frontiers in immunology · 2023
    Review
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Victor I AyalaAIDS and Cancer Virus Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD 21702-1201, USA.
Matthew T TrivettAIDS and Cancer Virus Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD 21702-1201, USA.
Lori V CorenAIDS and Cancer Virus Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD 21702-1201, USA.
Sumiti JainAIDS and Cancer Virus Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD 21702-1201, USA.
Patrick S BohnWisconsin National Primate Research Center, University of Wisconsin-Madison, Madison, WI, USA.
Roger W WisemanWisconsin National Primate Research Center, University of Wisconsin-Madison, Madison, WI, USA.
David H O'ConnorWisconsin National Primate Research Center, University of Wisconsin-Madison, Madison, WI, USA.
Claes OhlenAIDS and Cancer Virus Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD 21702-1201, USA.
David E OttAIDS and Cancer Virus Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD 21702-1201, USA. Electronic address: ottde@mail.nih.gov.
Leidos (United States) · USUniversity of Wisconsin–Madison · US

Funding

WNPRC Supplemental Request for Nonhuman Primate Enclosures to Equip HIV/AIDS-Related Research FacilitiesP51OD011106 · OD · UNIVERSITY OF WISCONSIN-MADISON · PI Dorota A. Grejner-Brzezinska · 2012 to 2026
$150.7M
ZOLEDRONATE PREVENTS BONE LOSS IN OVARIECTOMIZED RHESUS MONKEYSP51RR000167 · NCRR · UNIVERSITY OF WISCONSIN-MADISON · PI WATKINS, DAVID I · 1985 to 2011
$106.7M
Identifying Common T Cell Responses to Major Pathogens in Rhesus MacaquesR24OD017850 · OD · UNIVERSITY OF WISCONSIN-MADISON · PI O'CONNOR, DAVID H. · 2014 to 2022
$5.8M
CCR NIH HHS HHSN261200800001CIntramural NIH HHS Z99 CA999999NCI NIH HHS HHSN261200800001ENCRR NIH HHS P51 RR000167NIH HHS P51 OD011106NIH HHS R24 OD017850
6 · The paper itself

Abstract

To study CD4(+)T-cell suppression of AIDS virus replication, we isolated nine rhesus macaque SIVGag-specific CD4(+)T-cell clones. One responding clone, Gag68, produced a typical cytotoxic CD8(+)T-cell response: induction of intracellular IFN-γ, MIP-1α, MIP-1β, and CD107a degranulation. Gag68 effectively suppressed the spread of SIVmac239 in CD4(+)T cells with a corresponding reduction of infected Gag68 effector cells, suggesting that CD4(+)effectors need to suppress their own infection in addition to their targets to be effective. Gag68 TCR cloning and gene transfer into CD4(+)T cells enabled additional experiments with this unique specificity after the original clone senesced. Our data supports the idea that CD4(+)T cells can directly limit AIDS virus spread in T cells. Furthermore, Gag68 TCR transfer into CD4(+)T-cell clones with differing properties holds promise to better understand the suppressive effector mechanisms used by this important component of the antiviral response using the rhesus macaque model.

Indexed as

Virus ReplicationAnimalsCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesCells, CulturedClone CellsGene Products, gagMacaca mulattaReceptors, Antigen, T-CellSimian Immunodeficiency VirusT-Cell Antigen Receptor SpecificityGene Products, gagReceptors, Antigen, T-CellCytolytic CD4(+)T cellsSIVT-cell effectorsT-cell receptorTCR transductionVirus-specificVirus suppression

Identifiers

PMID27017056
PMCPMC4860118
OpenAlexW2305037870

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.